Tag Archive for: data presentation

Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025

/in

– Dr Paul Brennan to present on the association of early biomarker modulation with long term clinical outcomes from the MATCH Ph II study of non-engineered macrophages in cirrhosis – Dr Lara Campana to present on anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapy in models of liver fibrosis Edinburgh and London, UK, 9 October […]

Read more

New ublituximab data in multiple sclerosis to be presented at ECTRIMS Congress 2025 alongside partner TG Therapeutics

/in

Barcelona, Spain and Düsseldorf, Germany – 22 September, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces its participation at 41st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Annual Congress, taking place in Barcelona from 24–26 September. […]

Read more

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease.

/in

– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages. – RTX001 has recently entered into a Phase […]

Read more

Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024

/in

– Oral Presentation of complete data from the three-year MATCH Phase 2 trial – Poster Presentation demonstrating preclinical proof of concept of safety and efficacy of RTX001, an autologous engineered macrophage cell therapy for end stage liver disease Edinburgh and London, UK, 1 October 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company […]

Read more

Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference

/in

Professor Gertsch identifies novel transport mechanism and presents new information on mode of action as part of presentation entitled ‘Identification of an Endocannabinoid Reuptake and Recycling Machinery’ Presentation forms part of 10th Gordon Research Conference on ‘Cannabinoid Function in the CNS’ held 16-21 July 2023 outside Barcelona, Spain BASEL, Switzerland – 18 July 2023 – Synendos […]

Read more